Table 2. Results of the bivariate analysis of the T-cell immune response in women with a primary CMV infection.
| All women included (n = 60) | Non-transmitter (n = 36) | Transmitter (n = 24) | OR (CI 95%) | p-value | |
|---|---|---|---|---|---|
| Median (IQR) | |||||
| Gestational age at blood sample collection | 26.0 [21.0;31.2] | 25.5 [21.0;28.2] | 26.5 [22.8;32.2] | NA | 0.290 |
| Total lymphocyte count | 2300 [1955;2620] | 2305 [2062;2665] | 2195 [1822;2502] | 0.236 | |
| % CD3-CD8+ T cells | 24.6 [17.3;33.1] | 27.0 [21.1;34.1] | 23.9 [13.7;32.6] | 0.330 | |
| Total count CD3-CD8+ T cells | 579 [376;775] | 579 [407;908] | 574 [291;684] | 0.381 | |
| % CMV-specific CD8+IFNγ T cells | 0.58 [0.10;3.07] | 0.54 [0.11;3.07] | 0.58 [0.08;3.25] | 1.039 (0.943–1.153) | 0.988 |
| Total count CMV-specific CD8+IFNγ T cells | 3.31 [0.63;18.7] | 3.31 [0.76;21.3] | 3.33 [0.24;12.1] | 1.005 (0.991–1.02) | 0.868 |
| % CD3-CD4+ T cells | 36.8 [23.1;43.0] | 37.5 [28.3;42.9] | 36.8 [16.9;44.9] | NA | 0.639 |
| Total count of CD3-CD4+ T cells | 778 [427;1020] | 836 [583;1030] | 701 [364;945] | 0.196 | |
| % CMV-specific CD4+IFNγ T cells | 0.15 [0.02;0.88] | 0.20 [0.05;0.84] | 0.04 [0.00;1.18] | 1.171 (0.848–1.843) | 0.251 |
| Total count CMV-specific CD4+IFNγ T cells | 0.96 [0.14;5.19] | 1.44 [0.57;2.99] | 0.23 [0.00;10.0] | 1.014 (0.979–1.064) | 0.195 |
| Positive CD8 response (>0.1% IFNγ) | 43 (71.7%) | 27 (75.0%) | 16 (66.7%) | 0.667 (0.212–2.104) | 0.682 |
| Positive CD4 response (>0.1% IFNγ) | 30 (52.6%) | 19 (57.6%) | 11 (45.8%) | 0.623 (0.213–1.791) | 0.543 |
Total count and percentages of CD3-CD8+ and CD3-CD4+ T lymphocytes are shown, as well as the total counts and percentages of CMV-specific CD8+ and CD4+ T lymphocytes producing IFN-γ: IQR, Interquartile range; OR, Odds ratio; CI, Confidence Interval; NA, Not applicable (univariate analysis was not performed).